Blood test may replace biopsy for breast cancer subtyping
NCT ID NCT07574749
First seen May 09, 2026 · Last updated Jun 23, 2026 · Updated 8 times
Summary
This study is testing a new blood test that looks for tiny particles from breast cancer cells, called small extracellular vesicles (sEVs), to determine the cancer's molecular subtype. The goal is to see if this test is as accurate as the standard tissue biopsy. Researchers will compare results from the blood test with those from traditional pathology in 1500 people with advanced breast cancer. If it works, this could lead to a quicker, less invasive way to guide treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
diagnostic test using small extracellular vesicles (sEVs) on a microchip
What this could lead to
If successful, this could provide a faster, less invasive way to determine breast cancer subtypes, helping doctors choose the most effective treatment for each patient.
What could go wrong
This is an early-phase exploratory study, so the test may not prove accurate enough for routine use. It is also limited to patients with advanced breast cancer, so results may not apply to earlier stages.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.